Paper Details
- Home
- Paper Details
Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users.
Author: CicconePatrick E, GuJoan, ParasrampuriaDolly A, SchoedelKerri A, SchullerReinhard, SellersEdward M, SilberSteven A
Original Abstract of the Article :
The primary objective of this study was to determine if the abuse liability of methylphenidate is governed by formulation differences that affect rates of drug delivery. In this double-blind, placebo-controlled, randomized, crossover study, subjects with a history of recreational drug use received s...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://pubmed.ncbi.nlm.nih.gov/17873677
データ提供:米国国立医学図書館(NLM)
Methylphenidate: Exploring Formulation Differences and Abuse Liability
The field of [pharmacology] is constantly seeking to optimize drug delivery, ensuring that medications exert their desired effects while minimizing potential harms. This study takes a close look at [methylphenidate], a medication commonly used to treat [attention-deficit/hyperactivity disorder (ADHD)], examining the impact of different formulations on its abuse potential.
The study, conducted on individuals with a history of recreational drug use, compared the subjective effects of two different methylphenidate formulations: [immediate-release] and [extended-release]. The researchers were particularly interested in understanding how the rate of drug delivery, a key factor in the formulation differences, influenced the likelihood of abuse. It's like comparing two types of desert caravans, one with a fast-paced journey and the other with a more gradual pace, and observing how this difference in travel speed affects the travelers' experience.
Extended-Release Methylphenidate: Potentially Lower Abuse Liability
The study found that the extended-release formulation, with its slower release of methylphenidate into the bloodstream, resulted in consistently lower subjective effects compared to the immediate-release formulation, especially in the early hours after dosing. This suggests that the extended-release formulation might have a lower abuse potential.
Pharmacokinetic and Pharmacodynamic Considerations
The researchers also explored the relationship between the pharmacokinetics (how the drug moves through the body) and pharmacodynamics (how the drug affects the body) of methylphenidate. They found a correlation between the drug's blood levels and its subjective effects, suggesting that the way a drug is delivered can significantly influence its perceived effects.
Dr.Camel's Conclusion
This study provides valuable insights into the complexities of drug formulation and its influence on abuse potential. It reminds us that understanding the nuances of drug delivery is crucial for ensuring safe and effective treatment. As we continue to navigate the vast landscape of pharmacology, research like this will continue to guide us in optimizing drug development and patient care.
Date :
- Date Completed 2008-01-02
- Date Revised 2022-03-16
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.